Cargando…
FcRN receptor antagonists in the management of myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disorder characterized by autoantibodies specifically directed against proteins located within the postsynaptic membrane of the neuromuscular junction. These pathogenic autoantibodies can be reduced by therapies such as plasma exchange, IVIG infusions and othe...
Autores principales: | Bhandari, Vinaya, Bril, Vera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439012/ https://www.ncbi.nlm.nih.gov/pubmed/37602255 http://dx.doi.org/10.3389/fneur.2023.1229112 |
Ejemplares similares
-
FcRn inhibitors: a novel option for the treatment of myasthenia gravis
por: Zhu, Li-Na, et al.
Publicado: (2023) -
Characterization of the Rabbit Neonatal Fc Receptor (FcRn) and Analyzing the Immunophenotype of the Transgenic Rabbits That Overexpresses FcRn
por: Catunda Lemos, Ana Paula, et al.
Publicado: (2012) -
The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019) -
The neonatal Fc receptor in cancer FcRn in cancer
por: Cadena Castaneda, Diana, et al.
Publicado: (2020) -
Novel Treatments in Myasthenia Gravis
por: Menon, Deepak, et al.
Publicado: (2020)